Provention Bio Net Income
Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Provention Bio, as well as the relationship between them.
Provention Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Provention Bio's valuation are provided below:Provention Bio does not presently have any trending fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Provention |
Search Suggestions
| PR | Permian Resources | Company |
| PRIF-PG | Priorityome Fund | Company |
| PRAPX | Pimco Total Return | Mutual Fund |
| PRB | Van Eck | ETF |
| PRA | PRA | Cryptocurrency |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Provention Bio reported net income of (113.56 Million). This is 133.28% lower than that of the Pharmaceuticals sector and 262.13% lower than that of the Health Care industry. The net income for all United States stocks is 119.89% higher than that of the company.
Provention Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provention Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Provention Bio could also be used in its relative valuation, which is a method of valuing Provention Bio by comparing valuation metrics of similar companies.Provention Bio is currently under evaluation in net income category among its peers.
Provention Fundamentals
| Return On Equity | -0.98 | |||
| Return On Asset | -0.43 | |||
| Operating Margin | (9.94) % | |||
| Current Valuation | 607.28 M | |||
| Shares Outstanding | 91.1 M | |||
| Shares Owned By Insiders | 4.61 % | |||
| Shares Owned By Institutions | 53.20 % | |||
| Number Of Shares Shorted | 5.37 M | |||
| Price To Book | 5.31 X | |||
| Price To Sales | 289.70 X | |||
| Revenue | 12.89 M | |||
| Gross Profit | (63.42 M) | |||
| EBITDA | (98.72 M) | |||
| Net Income | (113.56 M) | |||
| Cash And Equivalents | 84.52 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 23.47 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 3.59 X | |||
| Book Value Per Share | 1.39 X | |||
| Cash Flow From Operations | (75.41 M) | |||
| Short Ratio | 1.53 X | |||
| Earnings Per Share | (1.52) X | |||
| Target Price | 23.8 | |||
| Number Of Employees | 174 | |||
| Beta | 2.46 | |||
| Market Capitalization | 2.38 B | |||
| Total Asset | 236.86 M | |||
| Z Score | 60.6 | |||
| Net Asset | 236.86 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Provention Stock
If you are still planning to invest in Provention Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provention Bio's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |